Abstract
Recent reports have shown gefitinib, epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI) induced marked improvement in ECOG performance status (PS) as first-line therapy in EGFR mutation-positive patients with extremely poor PS. EGFR mutations frequently occur in east-Asian, female, non-smoking, adenocarcinoma patients, however they are occasionally detected in patients with non-adenocarcinomas or with a heavy smoking history. We describe a case in which EGFR mutation was detected in a male, current smoker, squamous cell carcinoma (SCC) patient with PS 4, who showed a marked response to the first-line gefitinib therapy. EGFR mutational analysis is recommended even for SCC patients especially in east-Asian populations.
MeSH terms
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bone Neoplasms / radiotherapy
-
Bone Neoplasms / secondary
-
Carcinoma, Squamous Cell / diagnostic imaging
-
Carcinoma, Squamous Cell / drug therapy*
-
Carcinoma, Squamous Cell / enzymology
-
Carcinoma, Squamous Cell / genetics
-
Carcinoma, Squamous Cell / radiotherapy
-
Carcinoma, Squamous Cell / secondary
-
Combined Modality Therapy
-
Docetaxel
-
ErbB Receptors / antagonists & inhibitors*
-
Fatal Outcome
-
Gefitinib
-
Genes, erbB-1*
-
Humans
-
Lung Neoplasms / diagnostic imaging
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / enzymology
-
Lung Neoplasms / genetics
-
Male
-
Middle Aged
-
Neoplasm Proteins / antagonists & inhibitors*
-
Neoplasm Proteins / genetics
-
Palliative Care
-
Protein Kinase Inhibitors / therapeutic use*
-
Quinazolines / administration & dosage
-
Quinazolines / therapeutic use*
-
Severity of Illness Index
-
Smoking / adverse effects
-
Taxoids / administration & dosage
-
Tomography, X-Ray Computed
Substances
-
Antineoplastic Agents
-
Neoplasm Proteins
-
Protein Kinase Inhibitors
-
Quinazolines
-
Taxoids
-
Docetaxel
-
EGFR protein, human
-
ErbB Receptors
-
Gefitinib